Immunomodulatory activity of IR700-labelled affibody targeting HER2

Sharpe, A. H. Introduction to checkpoint inhibitors and cancer immunotherapy. Immunol. Rev. 276, 5–8 (2017).

Zhang, L. et al. Unique photochemo-immuno-nanoplatform against orthotopic xenograft oral cancer and metastatic syngeneic breast cancer. Nano Lett. 18, 7092–7103 (2018).

Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017).

Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541–550 (2018).

Nagarsheth, N., Wicha, M. S. & Zou, W. P. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 17, 559–572 (2017).

Garg, A. D. et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 31, 1062–1079 (2012).

Ogawa, M. et al. Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. Oncotarget 8, 10425–10436 (2017).

Tanaka, M. et al. Immunogenic cell death due to a new photodynamic therapy (PDT) with glycoconjugated chlorin (G-chlorin). Oncotarget 7, 47242–47251 (2016).

Hirschberg, H., Berg, K. & Peng, Q. Photodynamic therapy mediated immune therapy of brain tumors. Neuroimmun. Neuroinflamm. https://doi.org/10.20517/2347-8659.2018.31 (2018).

Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97–111 (2017).

Kobayashi, H. & Choyke, P. L. Near-infrared photoimmunotherapy of cancer. Acc. Chem. Res. 52, 2332–2339 (2019).

Mitsunaga, M. et al. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat. Med. 17, 1685–1691 (2011).

Zhen, Z. et al. Protein nanocage mediated fibroblast-activation protein targeted photoimmunotherapy to enhance cytotoxic T cell infiltration and tumor control. Nano Lett. 17, 862–869 (2017).

Burley, T. A. et al. Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment. Int. J. cancer 142, 2363–2374 (2018).

Okada, R. et al. The effect of antibody fragments on CD25 targeted regulatory T cell near-infrared photoimmunotherapy. Bioconjug. Chem. 30, 2624–2633 (2019).

Hussain, A. F. et al. SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells. Bioconjug. Chem. 22, 2487–2495 (2011).

Sato, K. et al. Photoinduced ligand release from a silicon phthalocyanine dye conjugated with monoclonal antibodies: a mechanism of cancer cell cytotoxicity after near-infrared photoimmunotherapy. ACS Cent. Sci. 4, 1559–1569 (2018).

Anderson, E. D., Gorka, A. P. & Schnermann, M. J. Near-infrared uncaging or photosensitizing dictated by oxygen tension. Nat. Commun. 7, 13378 (2016).

Sato, K. et al. Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aaf6843 (2016).

Mitsunaga, M. et al. Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy. BMC Cancer 12, 345 (2012).

Yan, M., Parker, B. A., Schwab, R. & Kurzrock, R. HER2 aberrations in cancer: Implications for therapy. Cancer Treat. Rev. 40, 770–780 (2014).

Arteaga, C. L. et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Oncol. 9, 16–32 (2012).

Burstein, H. J. The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med. 353, 1652–1654 (2005).

Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012).

Bates, J. P., Derakhshandeh, R., Jones, L. & Webb, T. J. Mechanisms of immune evasion in breast cancer. BMC Cancer. https://doi.org/10.1186/S12885-018-4441-3 (2018).

Altai, M. et al. In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors. Cancer Biother. Radiopharm. 28, 187–195 (2013).

Muchowicz, A. et al. Inhibition of lymphangiogenesis impairs antitumour effects of photodynamic therapy and checkpoint inhibitors in mice. Eur. J. Cancer 83, 19–27 (2017).

He, C. et al. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. Nat. Commun. 7, 12499 (2016).

Panieri, E. & Santoro, M. M. ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis. 7, e2253 (2016).

Ito, K. et al. Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms. BMC cancer 16, 37 (2016).

Ogata, F. et al. Dynamic changes in the cell membrane on three dimensional low coherent quantitative phase microscopy (3D LC-QPM) after treatment with the near infrared photoimmunotherapy. Oncotarget 8, 104295–104302 (2017).

Korbelik, M., Zhang, W. & Merchant, S. Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: surface expression of calreticulin and high-mobility group box-1 release. Cancer Immunol. Immunother. 60, 1431–1437 (2011).

Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860–875 (2012).

Castano, A. P., Mroz, P. & Hamblin, M. R. Photodynamic therapy and anti-tumour immunity. Nat. Rev. Cancer 6, 535–545 (2006).

Proskuryakov, S. Y., Konoplyannikov, A. G. & Gabai, V. L. Necrosis: a specific form of programmed cell death? Exp. Cell Res. 283, 1–16 (2003).

Blachere, N. E., Darnell, R. B. & Albert, M. L. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol. 3, e185 (2005).

Vinci, M. et al. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol. 10, 29 (2012).

Kramer-Marek, G., Kiesewetter, D. O. & Capala, J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J. Nucl. Med. 50, 1131–1139 (2009).

Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. Brit J. Cancer 102, 1555–1577 (2010).